|
1
|
De Sousa SM and Norman RJ: Metabolic
syndrome, diet and exercise. Best Pract Res Clin Obstet Gynaecol.
37:140–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Francesconi C, Lackinger C, Weitgasser R,
Haber P and Niebauer J: Physical activity and exercise training in
the prevention and therapy of type 2 diabetes mellitus. Wien Klin
Wochenschr. 128:S141–S145. 2016.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Endes S: Physical activity reduces
cardiovascular disease risk in older adults. Evid Based Med.
21:1912016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Navigante A and Morgado PC: Does physical
exercise improve quality of life of advanced cancer patients? Curr
Opin Support Palliat Care. 10:306–309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nyrop KA, Deal AM, Williams GR, Guerard
EJ, Pergolotti M and Muss HB: Physical activity communication
between oncology providers and patients with early-stage breast,
colon or prostate cancer. Cancer. 122:470–476. 2007. View Article : Google Scholar
|
|
6
|
Michaels C: The importance of exercise in
lung cancer treatment. Transl Lung Cancer Res. 5:235–238. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin KY, Frawley HC, Denehy L, Feil D and
Granger CL: Exercise interventions for patients with gynaecological
cancer: A systematic review and meta-analysis. Physiotherapy.
102:309–319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karstoft K and Pedersen BK: Skeletal
muscle as a gene regulatory endocrine organ. Curr Opin Clin Nutr
Metab Care. 19:270–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boström P, Wu J, Jedrychowski MP, Korde A,
Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, et al: A
PGC1-α-dependent myokine that drives brown-fat-like development of
white fat and thermogenesis. Nature. 481:463–468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu J, Boström P, Sparks LM, Ye L, Choi JH,
Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G, et al:
Beige adipocytes are a distinct type of thermogenic fat cell in
mouse and human. Cell. 150:366–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moon HS, Dincer F and Mantzoros CS:
Pharmacological concentrations of irisin increase cell
proliferation without influencing markers of neurite outgrowth and
synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism.
62:1131–1136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huh JY, Dincer F, Mesfum E and Mantzoros
CS: Irisin stimulates muscle growth-related genes and regulates
adipocyte differentiation and metabolism in humans. Int J Obes
(Lond). 38:1538–1544. 2014.PubMed/NCBI
|
|
13
|
Qiao X, Nie Y, Ma Y, Chen Y, Cheng R, Yin
W, Hu Y, Xu W and Xu L: Irisin promotes osteoblast proliferation
and differentiation via activating the MAP kinase signaling
pathways. Sci Rep. 6:187322016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colaianni G, Cuscito C, Mongelli T,
Pignataro P, Buccoliero C, Liu P, Lu P, Sartini L, Di Comite M,
Mori G, et al: The myokine irisin increases cortical bone mass.
Proc Natl Acad Sci USA. 112:pp. 12157–12162. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song H, Wu F, Zhang Y, Zhang Y, Wang F,
Jiang M, Wang Z, Zhang M, Li S, Yang L, et al: Irisin promotes
human umbilical vein endothelial cell proliferation through the ERK
signaling pathway and partly suppresses high glucose-induced
apoptosis. PLoS One. 9:e1102732014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu J, Xiang G, Liu M, Mei W, Xiang L and
Dong J: Irisin protects against endothelial injury and ameliorates
atherosclerosis in apolipoprotein E-Null diabetic mice.
Atherosclerosis. 243:438–448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song H, Xu J, Lv N, Zhang Y, Wu F, Li H,
Shao L, Mu Q, Wang F, Tang D, et al: Irisin reverses platelet
derived growth factor-BB-induced vascular smooth muscle cells
phenotype modulation through STAT3 signaling pathway. Biochem
Biophys Res Commun. 479:139–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Song H, Zhang Y, Wu F, Mu Q,
Jiang M, Wang F, Zhang W, Li L, Shao L, et al: Irisin inhibits
atherosclerosis by promoting endothelial proliferation through
microRNA126-5p. J Am Heart Assoc. 5:52016. View Article : Google Scholar
|
|
19
|
Provatopoulou X, Georgiou GP, Kalogera E,
Kalles V, Matiatou MA, Papapanagiotou I, Sagkriotis A, Zografos GC
and Gounaris A: Serum irisin levels are lower in patients with
breast cancer: Association with disease diagnosis and tumor
characteristics. BMC Cancer. 15:8982015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aydin S, Kuloglu T, Ozercan MR, Albayrak
S, Aydin S, Bakal U, Yilmaz M, Kalayci M, Yardim M, Sarac M, et al:
Irisin immunohistochemistry in gastrointestinal system cancers.
Biotech Histochem. 91:242–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Us Altay D, Keha EE, Yaman S Ozer, Ince I,
Alver A, Erdogan B, Canpolat S, Cobanoglu U and Mentese A:
Investigation of the expression of irisin and some cachectic
factors in mice with experimentally induced gastric cancer. QJM.
109:785–790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuloglu T, Celik O, Aydin S, Ozercan I
Hanifi, Acet M, Aydin Y, Artas G, Turk A, Yardim M, Ozan G, et al:
Irisin immunostaining characteristics of breast and ovarian cancer
cells. Cell Mol Biol (Noisy-le-grand). 62:40–44. 2016.PubMed/NCBI
|
|
23
|
Gannon NP, Vaughan RA, Garcia-Smith R,
Bisoffi M and Trujillo KA: Effects of the exercise-inducible
myokine irisin on malignant and non-malignant breast epithelial
cell behavior in vitro. Int J Cancer. 136:197–202. 2015. View Article : Google Scholar
|
|
24
|
Shao L, Li H, Chen J, Song H, Zhang Y, Wu
F, Wang W, Zhang W, Wang F, Li H and Tang D: Irisin suppresses the
migration, proliferation, and invasion of lung cancer cells via
inhibition of epithelial-to-mesenchymal transition. Biochem Biophys
Res Commun. 485:598–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaffney R, Unni KK, Sim FH, Slezak JM,
Esther RJ and Bolander ME: Follow-up study of long-term survivors
of osteosarcoma in the prechemotherapy era. Hum Pathol.
37:1009–1014. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosano L, Cianfrocca R, Spinella F, Di
Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG and Bagnato
A: Acquisition of chemoresistance and EMT phenotype is linked with
activation of the endothelin A receptor pathway in ovarian
carcinoma cells. Clin Cancer Res. 17:2350–2360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Davidson B, Tropé CG and Reich R:
Epithelial-mesenchymal transition in ovarian carcinoma. Front
Oncol. 2:332012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tu B, Du L, Fan QM, Tang Z and Tang TT:
STAT3 activation by IL-6 from mesenchymal stem cells promotes the
proliferation and metastasis of osteosarcoma. Cancer Lett.
325:80–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang
SW, Hwang WL and Tang CH: Interleukin-6 induces vascular
endothelial growth factor expression and promotes angiogenesis
through apoptosis signal-regulating kinase 1 in human osteosarcoma.
Biochem Pharmacol. 85:531–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen J, Wang S, Su J, Chu G, You H, Chen
Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3
signaling and reverses interleukin-6-induced epithelial-mesenchymal
transition, invasion, and metastasis in pancreatic cancer cells.
Onco Targets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meng J, Zhang XT, Liu XL, Fan L, Li C, Sun
Y, Liang XH, Wang JB, Mei QB, Zhang F, et al: WSTF promotes
proliferation and invasion of lung cancer cells by inducing EMT via
PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal.
28:1673–1682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu J, Zhang J, Shen B, Yin K, Xu J, Gao W
and Zhang L: Long noncoding RNA lncTCF7, induced by IL-6/STAT3
transactivation, promotes hepatocellular carcinoma aggressiveness
through epithelial-mesenchymal transition. J Exp Clin Cancer Res.
34:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dou L, Wang S, Sui X, Meng X, Shen T,
Huang X, Guo J, Fang W, Man Y, Xi J and Li J: MiR-301a mediates the
effect of IL-6 on the AKT/GSK pathway and hepatic glycogenesis by
regulating PTEN expression. Cell Physiol Biochem. 35:1413–1424.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Che Q, Liu BY, Wang FY, He YY, Lu W, Liao
Y, Gu W and Wan XP: Interleukin 6 promotes endometrial cancer
growth through an autocrine feedback loop involving ERK-NF-κB
signaling pathway. Biochem Biophys Res Commun. 446:167–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu YS, Chung I, Wong WF, Masamune A, Sim
MS and Looi CY: Paracrine IL-6 signaling mediates the effects of
pancreatic stellate cells on epithelial-mesenchymal transition via
Stat3/Nrf2 pathway in pancreatic cancer cells. Biochim Biophys
Acta. 1861:296–306. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pan J, Lee Y, Zhang Q, Xiong D, Wan TC,
Wang Y and You M: Honokiol decreases lung cancer metastasis through
inhibition of the STAT3 signaling pathway. Cancer Prev Res (Phila).
10:133–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xue D, Yang Y, Liu Y, Wang P, Dai Y, Liu
Q, Chen L, Shen J, Ju H, Li Y, et al: MicroRNA-206 attenuates the
growth and angiogenesis in non-small cell lung cancer cells by
blocking the 14-3-3ζ/STAT3/HIF-1α/VEGF signaling. Oncotarget.
7:79805–79813. 2016.PubMed/NCBI
|
|
41
|
Yuan H, Kajiyama H, Ito S, Yoshikawa N,
Hyodo T, Asano E, Hasegawa H, Maeda M, Shibata K, Hamaguchi M, et
al: ALX1 induces snail expression to promote
epithelial-to-mesenchymal transition and invasion of ovarian cancer
cells. Cancer Res. 73:1581–1590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qureshi R, Arora H and Rizvi MA: EMT in
cervical cancer: Its role in tumour progression and response to
therapy. Cancer Lett. 356(2 Pt B): 1–331. 2015.
|
|
44
|
Wu D, Cheng J, Sun G, Wu S, Li M, Gao Z,
Zhai S, Li P, Su D and Wang X: p70S6K promotes IL-6-induced
epithelial-mesenchymal transition and metastasis of head and neck
squamous cell carcinoma. Oncotarget. 7:36539–36550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee SO, Yang X, Duan S, Tsai Y, Strojny
LR, Keng P and Chen Y: IL-6 promotes growth and
epithelial-mesenchymal transition of CD133+ cells of
non-small cell lung cancer. Oncotarget. 7:6626–6638. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bharti R, Dey G and Mandal M: Cancer
development, chemoresistance, epithelial to mesenchymal transition
and stem cells: A snapshot of IL-6 mediated involvement. Cancer
Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Papiewska-Pająk I, Kowalska MA and Boncela
J: Expression and activity of SNAIL transcription factor during
epithelial to mesenchymal transition (EMT) in cancer progression.
Postepy Hig Med Dosw (Online). 70:968–980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Turley EA, Veiseh M, Radisky DC and
Bissell MJ: Mechanisms of disease: Epithelial-mesenchymal
transition - does cellular plasticity fuel neoplastic progression?
Nat Clin Pract Oncol. 5:280–290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kumari N, Dwarakanath BS, Das A and Bhatt
AN: Role of interleukin-6 in cancer progression and therapeutic
resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Saitoh M, Endo K, Furuya S, Minami M,
Fukasawa A, Imamura T and Miyazawa K: STAT3 integrates cooperative
Ras and TGF-β signals that induce Snail expression. Oncogene.
35:1049–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ,
Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, et al:
Macrophage-secreted IL-8 induces epithelial-mesenchymal transition
in hepatocellular carcinoma cells by activating the
JAK2/STAT3/Snail pathway. Int J Oncol. 46:587–596. 2015. View Article : Google Scholar : PubMed/NCBI
|
